

# On a journey to feel a little better. Or BEDDA.

<b>Submission date</b>	<b>Recruitment status</b>	<input checked="" type="checkbox"/> Prospectively registered
17/08/2022	No longer recruiting	<input checked="" type="checkbox"/> Protocol
<b>Registration date</b>	<b>Overall study status</b>	<input type="checkbox"/> Statistical analysis plan
20/08/2022	Completed	<input type="checkbox"/> Results
<b>Last Edited</b>	<b>Condition category</b>	<input type="checkbox"/> Individual participant data
02/12/2025	Mental and Behavioural Disorders	<input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

In this study, we aim to improve the detection and prevention of subclinical depression in an individual who has not previously met the full criteria for major depression and who currently experiences depressive symptoms. Detection and prevention can offer help before the subclinical depression becomes a full-blown depressive episode. Improving this detection and prevention is important because more and more people are suffering from subclinical and clinical depression.

### Who can participate?

Healthy individuals who are at least 18 years old and over with residency in Switzerland

### What does the study involve?

This study aims to improve the prevention of depression in students and the general public by developing digital biomarkers and a digital intervention called BEDDA. Participants interact with the digital health app for 30 sessions. To receive compensation, participants must complete these 30 sessions in 45 days or less. The digital health app called BEDDA consists of a conversational agent (i.e., chatbot), a gamified slow-paced breathing training, and actionable advice integrable into everyday life.

### What are the possible benefits and risks of participating?

Potential benefits include a reduction in symptoms of depression and anxiety and a stress reduction. Participants will learn a slow-paced breathing technique that may help them to calm down in stressful situations. To the best of our knowledge, the different components of BEDDA have not been associated with any health risks. For individuals excluded due to the severity of symptoms, we will provide information on how to find help from mental health services.

### Where is the study run from?

Center for Digital Health Interventions (ETH Zurich) (Switzerland)

### When is the study starting and how long is it expected to run for?

February 2021 to February 2026

Who is funding the study?

1. CSS health insurance (public health insurance Switzerland)
2. Center for Digital Health Interventions (ETH Zurich) (Switzerland)

Who is the main contact?

Prof. Dr. Tobias Kowatsch  
tobias.kowatsch@unisg.ch

## Contact information

**Type(s)**

Public, Principal investigator

**Contact name**

Prof Tobias Kowatsch

**ORCID ID**

<https://orcid.org/0000-0001-5939-4145>

**Contact details**

University of St.Gallen (HSG), Dufourstrasse 40a  
St. Gallen  
Switzerland  
9000  
+41 44 633 87 68  
• [tobias.kowatsch@unisg.ch](mailto:tobias.kowatsch@unisg.ch)

**Type(s)**

Scientific

**Contact name**

Mr Yanick Lukic

**ORCID ID**

<https://orcid.org/0000-0002-2576-6569>

**Contact details**

Center for Digital Health Interventions  
Weinbergstrasse 56/58  
Zürich  
Switzerland  
8006  
+41 44 633 87 68  
[ylukic@ethz.ch](mailto:ylukic@ethz.ch)

## Additional identifiers

**Clinical Trials Information System (CTIS)**

Nil known

**ClinicalTrials.gov (NCT)**

Nil known

**Protocol serial number**

EK 2022-N-31

## Study information

**Scientific Title**

Development of a digital biomarker and intervention for subclinical depression: Study protocol for a longitudinal waitlist control study

**Acronym**

BEDDA

### Study objectives

Due to the substantial number of voice features, formulating a hypothesis for investigating digital biomarkers for subclinical depression is difficult. However, related work reported differences in voice features depending on the severity of depression (Cummins et al., 2015; Low et al., 2020). Certain features (such as fundamental frequency, jitter, shimmer) extracted from voice and breathing should correlate higher with symptoms and severity of depression than other features (e.g., first and second formant variability), as this difference has been reported in Low et al. (2020). Similarly, we cannot predict feature importance for more elaborated machine learning models. For reported classification accuracy or predictive accuracy of existing work, we refer to the publications from Cummins et al. (2015) and Low et al. (2020).

Regarding the investigation of efficacy, we can formulate the hypothesis. We hypothesize that the intervention group using the slow-paced breathing training "Breeze" will show significant improvements in symptoms and severity of depression compared to a waitlist control.

---

Cummins, N., Scherer, S., Krajewski, J., Schnieder, S., Epps, J., & Quatieri, T. F. (2015). A review of depression and suicide risk assessment using speech analysis. In *Speech Communication* (Vol. 71, pp. 10–49). Elsevier B.V. <https://doi.org/10.1016/j.specom.2015.03.004>

Low, D. M., Bentley, K. H., & Ghosh, S. S. (2020). Automated assessment of psychiatric disorders using speech: A systematic review. In *Laryngoscope Investigative Otolaryngology* (Vol. 5, Issue 1, pp. 96–116). John Wiley and Sons Inc. <https://doi.org/10.1002/lio2.354>

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Approved 23/06/2022, ETH Zurich Ethics Commission (ETH Zurich Prof. Dr. Detlef Günther, HG F 57, Rämistrasse 101, 8092 Zurich, Switzerland; +41 44 63 28572; [ethics@sl.ethz.ch](mailto:ethics@sl.ethz.ch)), ref: EK 2022-N-31

**Study design**

Single-centre interventional double-blinded waitlist-controlled field study

**Primary study design**

Interventional

**Study type(s)**

Prevention

**Health condition(s) or problem(s) studied**

Prevention of depression

**Interventions**

Participants will be allocated using a computer algorithm script (Python) to either waitlist control or intervention group. Participants in the intervention group will start the intervention while participants in the waitlist control group will wait until the intervention group has finished the intervention.

Participants will interact with the digital intervention BEDDA consisting of a scripted conversational agent, a slow-paced breathing training called Breeze, and actionable advice for different symptoms. The intervention comprises 30 daily interactions the participants must complete in less than 45 days.

**Intervention Type**

Behavioural

**Primary outcome(s)**

1. Depression severity measured using the nine-question version of the Patient Health Questionnaire (PHQ-9) at baseline, after 14 interactions, and at the end of the intervention (after 30 interactions).
2. One of three randomly selected symptoms of depression (mood, agitation, anhedonia) measured using the Multidimensional Mood State Questionnaire (MDMQ) on a daily basis
3. Physiological (such as heart-rate-variability) and behavioral (such as physical activity) outcomes measured using a Garmin Smartwatch Fitness Tracker in a sub sample of 25% of the participants

**Key secondary outcome(s)**

Anxiety severity measured using the seven-question version of the General Anxiety Disorder questionnaire (GAD-7) and stress using the short version of the Trier Inventory for Chronic Stress at baseline, after 14 interactions, and at the end of the intervention (after 30 interactions)

**Completion date**

01/02/2026

**Eligibility**

**Key inclusion criteria**

1. Aged 18 years old and over
2. Residency in Switzerland
3. Understand of mid-level English or German (B1-B2)

**Participant type(s)**

Healthy volunteer

**Healthy volunteers allowed**

No

**Age group**

Mixed

**Lower age limit**

18 years

**Upper age limit**

99 years

**Sex**

All

**Total final enrolment**

0

**Key exclusion criteria**

1. Current diagnosis with or in treatment for a mental health disease
2. Asthma, COPD, or any other lung or respiratory tract disease
3. Pregnancy
4. Scoring greater than 15 for symptom severity of depression and anxiety in the PHQ-9 and GAD-7 instruments, respectively
5. Positive response to the last question of the PHQ-9, assessing suicide ideation or self-harm

**Date of first enrolment**

17/10/2022

**Date of final enrolment**

31/10/2023

## Locations

**Countries of recruitment**

Switzerland

**Study participating centre**

**Center for Digital Health Interventions**

ETH Zurich

Weinbergstrasse 56/58

Zurich

Switzerland

8006

## Sponsor information

**Organisation**  
ETH Zurich

**ROR**  
<https://ror.org/05a28rw58>

## Funder(s)

**Funder type**  
University/education

**Funder Name**  
CSS Health Insurance

**Funder Name**  
Eidgenössische Technische Hochschule Zürich

**Alternative Name(s)**  
ETH Zurich, ETH Zürich, Federal Institute of Technology Zurich, ETH Zürich (Eidgenössische Technische Hochschule Zürich), Eidgenössische Technische Hochschule Zürich (Switzerland), Eidgenössische Technische Hochschule Zürich (ETH), ethzurich, ETH

**Funding Body Type**  
Private sector organisation

**Funding Body Subtype**  
Universities (academic only)

**Location**  
Switzerland

## Results and Publications

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**  
Data sharing statement to be made available at a later date

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Protocol article</a>		22/06/2023	23/06/2023	Yes	No

<a href="#"><u>Participant information sheet</u></a>		19/08/2022	No	Yes
<a href="#"><u>Participant information sheet</u></a>		19/08/2022	No	Yes
<a href="#"><u>Participant information sheet</u></a>		19/08/2022	No	Yes
<a href="#"><u>Participant information sheet</u></a>	Participant information sheet	11/11/2025	11/11/2025	No
<a href="#"><u>Study website</u></a>	Study website	11/11/2025	11/11/2025	No